GlaxoSmithKline (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2020

  1. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

    Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 3, pp. 325-330

2002

  1. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy

    Antiviral Therapy, Vol. 7, Núm. 1, pp. 43-51